Takeda Pharmaceutical Co. said Tuesday it will team up with enGene Inc. of Canada to develop novel medicines for gastrointestinal diseases.
Takeda will be responsible for all clinical development and commercialization of the medicines, using the gene delivery platform of the Canadian biotech company.
The Japanese pharmaceutical company will develop medicines and therapies for diseases that are difficult to cure, such as Crohn’s disease and ulcerative colitis, which are marked by inflammation of the lining of the gastrointestinal tract.
Osaka-based Takeda views digestive system disorders as a priority area and is seeking collaboration with overseas companies.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.